Weingartner H - Search Results

1

Measurement and interpretation of changes in memory in response to drug treatments.

Weingartner H, Eckardt M, Molchan S, Sunderland T, Wolkowitz O. Weingartner H, et al. Psychopharmacol Bull. 1992;28(4):331-40. Psychopharmacol Bull. 1992. PMID: 1296214 Review.

2

Clinical relevance of effects of benzodiazepines on learning and memory.

Lister RG, Weingartner H, Eckardt MJ, Linnoila M. Lister RG, et al. Among authors: weingartner h. Psychopharmacol Ser. 1988;6:117-27. doi: 10.1007/978-3-642-73288-1_8. Psychopharmacol Ser. 1988. PMID: 2905802 Review.

3

Cognitive effects of L-deprenyl in Alzheimer's disease.

Tariot PN, Sunderland T, Weingartner H, Murphy DL, Welkowitz JA, Thompson K, Cohen RM. Tariot PN, et al. Among authors: weingartner h. Psychopharmacology (Berl). 1987;91(4):489-95. doi: 10.1007/BF00216016. Psychopharmacology (Berl). 1987. PMID: 3108930 Clinical Trial.

4

Pharmacologic challenges in Alzheimer disease and normal controls: cognitive modeling in humans.

Sunderland T, Molchan SE, Little JT, Bahro M, Putnam KT, Weingartner H. Sunderland T, et al. Among authors: weingartner h. Alzheimer Dis Assoc Disord. 1997;11 Suppl 4:S23-6. Alzheimer Dis Assoc Disord. 1997. PMID: 9339269 Review.

5

The effects of thyrotropin-releasing hormone and scopolamine in Alzheimer's disease and normal volunteers.

Molchan SE, Mellow AM, Hill JL, Weingartner H, Martinez R, Vitiello B, Sunderland T. Molchan SE, et al. Among authors: weingartner h. J Psychopharmacol. 1992 Jan;6(4):489-500. doi: 10.1177/026988119200600404. J Psychopharmacol. 1992. PMID: 22291397 Free article.

6

Low-dose oral lorazepam administration in Alzheimer subjects and age-matched controls.

Sunderland T, Weingartner H, Cohen RM, Tariot PN, Newhouse PA, Thompson KE, Lawlor BA, Mueller EA. Sunderland T, et al. Among authors: weingartner h. Psychopharmacology (Berl). 1989;99(1):129-33. doi: 10.1007/BF00634466. Psychopharmacology (Berl). 1989. PMID: 2506598 Clinical Trial.

7

Intravenous nicotine in Alzheimer's disease: a pilot study.

Newhouse PA, Sunderland T, Tariot PN, Blumhardt CL, Weingartner H, Mellow A, Murphy DL. Newhouse PA, et al. Among authors: weingartner h. Psychopharmacology (Berl). 1988;95(2):171-5. doi: 10.1007/BF00174504. Psychopharmacology (Berl). 1988. PMID: 3137593 Clinical Trial.

8

Cognitive and behavioral sensitivity to scopolamine in Alzheimer patients and controls.

Sunderland T, Tariot PN, Mueller EA, Murphy DL, Weingartner H, Cohen RM. Sunderland T, et al. Among authors: weingartner h. Psychopharmacol Bull. 1985;21(3):676-9. Psychopharmacol Bull. 1985. PMID: 3898182 Clinical Trial. No abstract available.

9

Scopolamine challenges in Alzheimer's disease.

Sunderland T, Tariot P, Murphy DL, Weingartner H, Mueller EA, Cohen RM. Sunderland T, et al. Among authors: weingartner h. Psychopharmacology (Berl). 1985;87(2):247-9. doi: 10.1007/BF00431817. Psychopharmacology (Berl). 1985. PMID: 3931154 Clinical Trial.

10

Fluvoxamine treatment of alcoholic amnestic disorder.

Martin PR, Adinoff B, Lane E, Stapleton JM, Bone GA, Weingartner H, Linnoila M, Eckardt MJ. Martin PR, et al. Among authors: weingartner h. Eur Neuropsychopharmacol. 1995 Mar;5(1):27-33. doi: 10.1016/0924-977x(94)00129-y. Eur Neuropsychopharmacol. 1995. PMID: 7542052 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

202 results

Search Page

Filters